Pre-Cure

Pre-Cure has developed an advanced multifunctional tumor-on-a-chip platform designed to transform cancer treatment selection and accelerate drug development. By integrating bio-convergence technologies—specifically 3D cell culture models, tissue engineering, and 3D-printed microfluidic devices—the platform creates physiologically relevant conditions that mimic the human tumor microenvironment. This technology allows for the rapid, parallel, and high-content assessment of multiple therapy responses, providing a dynamic view of how cancer cells behave outside the body. Unlike traditional models, Pre-Cure’s system extracts functional biological data from patient-derived samples, enabling a more accurate, personalized approach to oncology.

This technology is critical for physicians and pharmaceutical researchers seeking to improve patient outcomes and de-risk preclinical drug candidates. For clinicians, the platform supports treatment decision-making by predicting the efficacy of various therapies, including monotherapy and combinations, from the first line of care. For biopharma partners, Pre-Cure provides contract research services using standardized metrics, such as a proprietary Sensitivity Index, to quantify drug efficacy and prioritize therapeutic candidates. The company is currently collaborating with leading medical centers to validate its technology across multiple cancer types and is expanding its infrastructure to better serve both clinical and research markets internationally.